A pilot study of lung ultrasound as point of care evaluation in post-COVID-19 patients

Not Applicable

Completed

• Conditions: Post COVID-19 (SARS-CoV-2 infection) imaging surveillance; Infections and Infestations

• Registration Number: ISRCTN14376817
• Lead Sponsor: Maidstone and Tunbridge Wells NHS Trust

Brief Summary

Poster results see attached file ISRCTN14376817 COVIDLUSPoster.pdf (added 12/12/2022) 2023 Results article in https://doi.org/10.1016/j.rmed.2023.107176 (added 03/03/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-01-06
• Study Completion: 2022-03-18
• Last Update Posted: 13 March 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

1. Aged 18-80 years
2. Positive sample for SARS-CoV-2 (detected by RT-PCR from a nasopharyngeal swab)
3. Admitted to hospital due to/with COVID-19

Added 03/03/2021:
4. Lung infiltrates on chest X-ray

Exclusion Criteria

At baseline:
1. Unable to mobilise independently
2. Visually or cognitively impaired
3. Unable to provide informed consent

Added 08/01/2021:
4. Pregnancy

Added 03/03/2021:
5. Allergy to CT contrast

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Current primary outcome measure as of 03/03/2021:<br> 1. The overall diagnostic accuracy of LUS as a test to identify pulmonary fibrosis as compared to CT thorax in post-COVID patients, assessed by calculating the sensitivity, specificity, positive predictive value, negative predictive values of LUS at Day 84<br> 2. The utility of Lung Ultrasound (LUS) to sequentially monitor interstitial changes in the lungs of 20 patients who have recently recovered from COVID-19 pneumonia, assessed using a validated LUS scoring system at Days 1, Day 42 and Day 84<br><br> Previous primary outcome measure::<br> Lung fibrosis and interstitial changes measured using lung ultrasound (LUS) at Day 1 and Day 84<br>